Trasylol, manufactured by Bayer, has been linked to serious, life-threatening side effects including heart attacks, strokes, encephalopathy, kidney failure and death.
Trasylol has been marketed by Bayer for 14 years. Bayer marketed it forcefully until it was used in approximately 1/3 of all cardiac bypass surgeries. In the last two years, Trasylol has been linked to approximately 22,000 deaths.
RECALL ALERT UPDATE: Bayer Pharmaceuticals Corp has at the request of the U.S. Food & Drug Administration (FDA) suspended sales of its antibleeding drug Trasylol, amid growing evidence that the drug may be linked to a higher risk of death than that of competing drugs.
What is the problem with Trasylol?
Trasylol was commonly administered in the operating room before heart surgery to reduce the risk of bleeding. Recently, it has been brought to the public attention that if Bayer had removed Trasylol from the market two years ago, it might have been able to prevent over 22,000 deaths. Concerns about the drug began back in the early 1980s. A survey of 20 patients was performed in 1992. Of those 20 patients, 13 began suffering from kidney problems after receiving the Trasylol injection. In 1993, the FDA approved Trasylol for use in patients at high risk of bleeding, and, in 1998, they expanded the use to all bypass surgery patients. A study connecting Trasylol and serious side effects was presented in January 2006, but the drug was not recalled until November 2007. Bayer failed to present their research to the FDA in their September 2006 meeting. The chairman of that FDA advisory panel, Dr. William Hiatt, said that he would have voted for a Trasylol recall back in 2006 if Bayer had not withheld the data from their study.
Side Effects of Trasylol
There are a variety of side effects associated with Trasylol. Our firm is pursing the following types of serious, life-threatening side effects:
- Heart Attack
- Renal Failure